

Vetter

Facts Figures Data

A leading expert for the development, manufacturing and packaging of aseptically prefilled drug-delivery systems





GT 33

This is Vetter

1950

70+ years of experience

7 countries

are home to our production facilities (Germany, Austria, USA) as well as our sales organizations (South Korea, Japan, China, Singapore)

6,300

Vetter employees worldwide



210M

filled units of injectable medicines in 2023



221M EUR

investment volume 2023

1,002M EUR

sales 2023

21

different filling lines in European and US production facilities



80%

of our projects deal with complex biologics

Awards

- CDMO Leadership Awards (2017-2024)
- Leading Employer Award (2023, 2024)
- Environmental Management Award (2023)
- PDA Drug Delivery Innovation Award (2023)
- Best Managed Companies Award (2020-2023)
- Top Digital Company (2023)
- Sustainable Impact on Employees Award (2022, 2023)
- Frost & Sullivan Global Customer Value Leadership Award (2021, 2023)
- Innovative Mobility Concepts Award (2022)
- Climate Mobility Challenge Award (2022)



Vetter Portfolio


As one of the world's leading Contract Development and Manufacturing Organizations (CDMO) for the production of injectable drug products, Vetter works with numerous large and small pharma and biotech companies. The service portfolio ranges from clinical to commercial filling and packaging of drugs in syringes and other drug-delivery systems. This expertise enables patients to access treatments for cancer, multiple sclerosis and severe rheumatoid arthritis, among other diseases.

The company's experience and competence support customers already in the early development phases of drug products for clinical trials prior to regulatory approval. A wide range of testing and analytical methods are used.

Drugs that have been approved are manufactured on behalf of the customer. Vetter takes care of all steps, from preparation to aseptic filling and manual or automatic visual inspection. An optimal product life cycle contributes to achieving the full potential of the compounds, often developed over many years.

In addition, Vetter offers a wide range of options for primary and secondary packaging, including the tamper-evident closure V-OVS®, as well as comprehensive serialization services. The CDMO's many years of valuable experience in dealing with regulatory authorities flows into all projects.





From a small pharmacy to Ravensburg's largest employer

Vetter was founded in 1950 as a small pharmacy in Ravensburg, Germany and made a name for itself with the formulation of the stomach remedy Ullus® capsules.

Today, the family-owned company is a global player with its headquarters still in Ravensburg: for more than 6,300 employees, Vetter is an attractive employer and the largest in the city – with three production sites in and around Ravensburg as well as development sites in Austria and the USA.

Over the course of its 70 year history, the CDMO has developed into an international market leader in the manufacturing of injectable drug products. High quality paired with modern technologies and decades of experience make Vetter a competent and trusted partner for innovative pharma and biotech companies. The company plays an important role in reliably supplying patients all over the world with vital and often life-saving medications.


The Vetter standard of quality

Pharma and biotech companies around the world need trusted partners. For developers of new medicines, this collaboration is important to meet the increasing demand for complex filling and packaging solutions of drug-delivery systems such as syringes, vials and cartridges.

Customers appreciate Vetter's quality and flexibility. About 80 percent of all projects are for biologics. Their filling and packaging is a challenge, because biotechnological drugs are complex and particularly sensitive. As an experienced solution provider, Vetter supports customers along the entire life cycle of their products – from early clinical development through to approval and worldwide market supply.

Every single employee at Vetter is aware of his or her responsibility towards patients and acts according to the principle:

Rely on us.





Innovations for patients

Innovations and the further development of technologies are firmly anchored in Vetter's corporate strategy to provide high quality drug products for all patients.

- Flexibility and the highest possible safety and quality standards through Vetter Clean Room Technology (V-CRT®): In Vetter's cleanrooms, RABS (Restricted Access Barrier System) and isolator technology is combined. This innovative process is protected under the brand name V-CRT®.
- Lyophilization expertise: Specialists in freeze-drying (lyophilization) work here. This process, specially developed for sensitive, active ingredients, preserves bioactivity and extends shelf life.
- Homecare made easy: Vetter's dual-chamber technologies enable the separate filling of different substances within one system. They are only combined immediately before injection. Dual-chamber systems offer patients and caregivers easy handling with very high dosing accuracy. This makes them ideal for use at home. Vetter is the leading supplier of these systems and holds patents for the double-chamber syringe Vetter Lyo Ject® and the double-chamber cartridge V-LK®.
- On the safe side: the tamper-evident closure V-OVS® prevents medication counterfeiting and protects patients. Immediately before use, a seal is broken that proves the untampered condition of the product.

Family-owned business and global player

Vetter is a globally active company with strong roots. The headquarters are still in Ravensburg, Germany. At the same time, the family-owned company operates further state-of-the-art production sites in Europe and the USA. A clinical production facility in Rankweil, Austria, has been in operation since 2021. The US development site and the US subsidiary are located in the Greater Chicago area.

The CDMO is also present in the Asia-Pacific markets of Singapore, Japan, South Korea and China, with its own sales locations and is thus always close to its customers. In this way, the medications produced by Vetter contribute to improving the quality of life for patients worldwide.



The managing directors of the family-owned company are Thomas Otto and Peter Soelkner (from left).





Responsibility for the future

As a globally active pharmaceutical service provider, Vetter is aware of its responsibility toward its employees, society and the environment. Acting in an economically, ecologically and socially responsible manner is firmly anchored in the corporate strategy across five key themes:

Corporate Compliance

is an integral part of all business activities at Vetter. The corporate compliance system and the Vetter Code of Conduct meet increasing customer demands for legal requirements and strictly observe the company's own ethical guidelines and goals.

Environment

As a company in an energy-intensive industry, Vetter bears special responsibility and therefore sets itself ambitious ecological goals, far beyond legal requirements. This involves the efficient use of energy and raw materials, the reduction of CO₂ emissions and the use of green technologies. Vetter generated 7.3 million kWh of renewable energy in 2022.

Health and Family

As a family business, the focus is on creating the best possible working conditions and promoting the health of all employees through preventive measures.

Under the name "Vetter Health", the company's health management offers comprehensive activities – from sports courses to ergonomics and nutrition tips to many other initiatives to maintain employee health. Also in the program: tailor-made possibilities to combine work and family. Flexible working time models are just as much a part of this as support with child care and a holiday program regularly organized by the company for employees' children.

Education

Knowledge is the basis for meeting Vetter's high quality standards. Therefore, the company invests in a wide range of educational initiatives for all ages. In the company's own training center, roughly 150 junior staff members receive comprehensive and practice-oriented qualifications for a variety of professions. By participating in nationwide initiatives such as "Girls Day" and "Building a Future with the MINT Subjects", Vetter inspires young people for apprenticeships and courses of study in mathematics, computer science, natural sciences and technology. An important component of the internal promotion culture is the Vetter Academy. Employees can individually develop professionally and personally with numerous educational contents and optimally upskill to their full potential.

Social Commitment

At Vetter, social responsibility goes beyond the company itself. In addition to manufacturing important medications, the family-owned company has the ambition to give back to society. Therefore, the CDMO is involved in promoting and supporting various social projects and non-profit organizations – from local and regional to international initiatives.

Vetter's timeline of success

1950



Foundation of company

Development and distribution of Ullus® Capsules

1970



Entry into aseptic production in Ravensburg's Schuetzenstrasse

Prefilled syringes become a manufacturing focus

1960



Innovative pharmaceutical packaging processes developed

Start as a contract manufacturer


1980



Opening of the US sales office

Prototype of the Vetter Lyo-Ject®

1990



Automation of production processes

Start of the production plant in Langenargen

2010



Opening of first international production facility in Chicago, IL, USA

Start of Center for Visual Inspection and Logistics in Ravensburg-Erlen

Opening of sales offices in Singapore, Japan and South Korea

2020



Publication of Vetter's first sustainability report

CO2 neutrality achieved at all worldwide locations

Move into the new company headquarters in Ravensburg Kammerbrühl

Expansion of Development Services with new location in Rankweil, Austria

Opening of Vetter training center

Foundation of sales office in China

Total number of employees reaches 6,000

2000



Further development into a provider of full-service solutions

Start-up of production and packaging site Ravensburg-Mariatal

Contact us

Vetter Pharma International GmbH
Markus Kirchner
Corporate Spokesperson / Media Relations
Phone: +49 (0)751-3700-3729
E-Mail: markus.kirchner@vetter-pharma.com

You can find more information at:

www.vetter-pharma.com at our [download-center](#).

For up-to-date information on the company
follow us here:



And subscribe to our channel here 